Skip to content
etf.net

Launched

Amplify Weight Loss Drug & Treatment ETF

THNRNYSE ArcaAmplifyC

$25.90−0.05 (−0.19%)

As of Nov 2, 2026, 3:59 PM ET

C44/ 100

Rank 7 of 9 in Pharma & Therapeutics

C44/100Rank 7 of 9inPharma & Therapeutics
Intraday session: down, 78 prints from 25.95 to 25.90. Range 25.86 to 26.02. Use the arrow keys to read each point.25.8526.0010 AM12 PM2 PM4 PM
Expense ratio
0.59%
Fund size
$6M
1Y total return
+13.2%
Yield · Last 12 months
1.59%
Holdings
22
Avg volume · 30D
1.48K sh
52W range
low $23.15high $27.94
Launched

The ETF.net THNR Grade

C

Score 44 out of 100

Category
Pharma & Therapeutics⁠
Rank
7 of 9
Six-pillar profile for THNR. Scores out of 100: Cost 41, Risk 40, Mission 63, Tradability 21, Holdings 65, Durability 18. Strongest: Holdings (65). Weakest: Durability (18). Leans toward Holdings and Mission.

Score 44 of 100 falls in the C band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.

  • Cost

    The fund’s net expense ratio, ranked against its category.
    C41 out of 100
    Rank 5 of 9

  • Mission

    Whether the fund did what it promised, tested against its stated mandate.
    B63 out of 100
    Rank 6 of 6

  • Risk

    How the fund held up when markets fell: downside volatility, drawdowns and tail loss.
    C40 out of 100
    Rank 7 of 9

  • Tradability

    How easy the fund is to trade: daily volume, and how far its price strays from net asset value.
    F21 out of 100
    Rank 8 of 9

  • Holdings

    How concentrated the fund is, and how complete and current its disclosed holdings are.
    B65 out of 100
    Rank 4 of 9

  • Durability

    Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.
    F18 out of 100
    Rank 9 of 9

Our read on THNR

ETF.net Research

In short

CThe GLP-1 trade in one ticker. THNR follows a global index of weight-loss drug developers plus the telehealth and treatment companies the index counts as economic beneficiaries, not just the obvious pharma giants.

Stated mandate

The fund provides access to global companies involved in weight-loss drug development or expected to benefit economically from increased use of these treatments, including drug manufacturers and telehealth providers.

Why people hold it

  • Casts wider than the drugmakers: the mandate covers telehealth providers and other firms tied to rising use of weight-loss treatments.amplifyetfs.com
  • Rules-based, not a hunch. It tracks VettaFi's Weight Loss Drug & Treatment Index (THINR), so the lineup changes by published methodology.
  • Global by design, so European drugmakers count as much as US ones. Launched in 2024, as GLP-1 treatments moved from niche to headline.

Worth knowing

  • The 0.59% expense ratio runs a touch above what global thematic funds typically charge.
  • A small fund that trades lightly, so spreads can be wider than on big index funds. Limit orders are the usual tool here.
  • One storyline, one drug class. Concentrated by construction, and distributions land annually or semiannually rather than as steady income.

THNR Performance

Launched May 21, 2024

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

Not enough history yet.Not enough history yet.Not enough history yet.
THNR$11,318
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$11,199
Oct 31, 2025 to Oct 30, 2026. THNR $11,318. SPY $11,199. Use the arrow keys to read each point.$10,000$11,000$12,000Oct 2025Apr 2026Oct 2026

Oct 31, 2025 – Oct 30, 2026

Returns run to the Oct 30, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for THNR. Periods over one year show the average yearly return.
PeriodTHNR
Year to date+2.9%
1 month+3.2%
3 months+2.2%
1 year+13.2%
3 yearsFund is under 3 years oldper yearNo data
5 yearsFund is under 5 years oldper yearNo data
10 yearsFund is under 10 years oldper yearNo data

With distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for THNR
YearReturn barTHNR
2026 YTD+2.9%
2025+13.7%
2024−10.4%

Since listing, May 21, 2024

THNR in the news

THNR Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Oct 30, 2026.
1.59%Last 12 months
Payout per share
$0.41Last 12 months
Last payment
$0.41 per share
Paid on
Shares bought on or after this date do not qualify for this distribution.
Frequency
Irregular

Distribution history

2024–2026

One bar per payment. 2 payments from 2024 to 2026 YTD. Dec 30, 2024 $0.22; Dec 30, 2025 $0.41. Use the arrow keys to read each point.202420252026YTD
Ex-datePay dateAmount per share
Dec 30, 2025Dec 31, 2025$0.41
Dec 30, 2024Dec 31, 2024$0.22

$10,000 in THNR 1 year ago paid $177 in dividends.

THNR Risk

Risk pillarC40 out of 100Rank 7 of 9 in Pharma & Therapeutics
How much the fund’s monthly returns vary, scaled to a year.
15.0%
Annualised · 29 months to Oct 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
−0.07
vs 3-month T-bills · 29 months to Oct 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−32.5%
29 months · trough Apr 2025
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
0.43
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

FMP measures it over up to five years of monthly returns.

THNR Cost

Compare THNR and PBPH

Overpaying vs PBPH, cheapest in Pharma & Therapeutics

$8,909

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

  • THNR 0.59%

    $11,635

  • PBPH 0.13% Cheapest

    $2,726

$10,000
30 years

Cost over time

  • THNR 0.59%
  • PBPH 0.13%
  • Overpaying
One line per fund, from year 0 to year 30. Use the arrow keys to read each point.$0$2.5K$5K$7.5K$10K$12.5K051015202530THNR $11,635PBPH $2,726

Year by year

YearTHNRPBPHOverpaying
10$1,058$238$820
20$4,051$930$3,121
30$11,635$2,726$8,909

Other funds in Pharma & Therapeutics

See others